NZ Hepatitis Research Review Issue 45

In this issue:

  -  Plasma and breast milk pharmacokinetics of tenofovir alafenamide
  -  HCV virologic response at 4 weeks with glecaprevir/pibrentasvir
  -  Global change in HCV prevalence between 2015 and 2020
  -  Liver injury after SARS-CoV-2 vaccination
  -  Glecaprevir/pibrentasvir for HCV in patients aged ≥75 years
  -  Four weeks of treatment with glecaprevir/pibrentasvir
  -  HCV-related depression, anxiety, and neurocognitive performance
  -  Mortality in people with chronic HBV infection
  -  Point-of-care HCV testing at community pharmacies

Please login below to download this issue (PDF)